Mark W. Garrison

1.2k total citations
33 papers, 909 citations indexed

About

Mark W. Garrison is a scholar working on Pharmacology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Mark W. Garrison has authored 33 papers receiving a total of 909 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 14 papers in Epidemiology and 12 papers in Infectious Diseases. Recurrent topics in Mark W. Garrison's work include Antibiotics Pharmacokinetics and Efficacy (14 papers), Antibiotic Resistance in Bacteria (11 papers) and Pneumonia and Respiratory Infections (10 papers). Mark W. Garrison is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (14 papers), Antibiotic Resistance in Bacteria (11 papers) and Pneumonia and Respiratory Infections (10 papers). Mark W. Garrison collaborates with scholars based in United States, Germany and Canada. Mark W. Garrison's co-authors include John C. Rotschafer, Douglas M. Campbell, Jeffrey D. Anderson, Donald E. Anderson, Keith A. Rodvold, Randy D. Pryka, Kyle Vance‐Bryan, John P. Toscano, T. A. Larson and Patrice Watson and has published in prestigious journals such as Journal of Clinical Microbiology, Antimicrobial Agents and Chemotherapy and Pharmaceutical Research.

In The Last Decade

Mark W. Garrison

33 papers receiving 860 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark W. Garrison United States 15 356 298 296 289 232 33 909
Michael A. Pfaller United States 18 471 1.3× 211 0.7× 316 1.1× 389 1.3× 299 1.3× 27 1.0k
P. G. Pitsakis United States 16 652 1.8× 221 0.7× 457 1.5× 307 1.1× 234 1.0× 24 1.1k
Meridith E. Erwin United States 15 376 1.1× 370 1.2× 293 1.0× 293 1.0× 398 1.7× 44 887
Helen T. Fernandez United States 19 417 1.2× 170 0.6× 299 1.0× 242 0.8× 141 0.6× 26 865
Kevin W. Ward United States 13 424 1.2× 258 0.9× 315 1.1× 195 0.7× 380 1.6× 26 885
Gerald A. Denys United States 17 246 0.7× 223 0.7× 154 0.5× 384 1.3× 264 1.1× 46 850
C Watanakunakorn United States 20 408 1.1× 193 0.6× 199 0.7× 527 1.8× 166 0.7× 47 1.1k
A. Evans United States 13 576 1.6× 191 0.6× 437 1.5× 223 0.8× 185 0.8× 15 882
A Buré France 14 270 0.8× 249 0.8× 125 0.4× 312 1.1× 433 1.9× 45 884
Carmen Betriú Spain 20 451 1.3× 259 0.9× 331 1.1× 406 1.4× 323 1.4× 55 1.1k

Countries citing papers authored by Mark W. Garrison

Since Specialization
Citations

This map shows the geographic impact of Mark W. Garrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Garrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Garrison more than expected).

Fields of papers citing papers by Mark W. Garrison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Garrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Garrison. The network helps show where Mark W. Garrison may publish in the future.

Co-authorship network of co-authors of Mark W. Garrison

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Garrison. A scholar is included among the top collaborators of Mark W. Garrison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Garrison. Mark W. Garrison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pfaller, Michael A., Dee Shortridge, Mark W. Garrison, et al.. (2021). Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018. International Journal of Infectious Diseases. 112. 321–326. 15 indexed citations
2.
Garrison, Mark W., et al.. (2012). Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA. Expert Review of Anti-infective Therapy. 10(10). 1087–1103. 16 indexed citations
3.
Garrison, Mark W., Reinier Mutters, & Michael J. Dowzicky. (2009). In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagnostic Microbiology and Infectious Disease. 65(3). 288–299. 37 indexed citations
4.
Garrison, Mark W., et al.. (2006). Antibiotic Selection and Resistance Issues with Fluoroquinolones and Doxycycline Against Bioterrorism Agents. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 26(1). 3–14. 24 indexed citations
5.
Garrison, Mark W., et al.. (2006). In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. International Journal of Antimicrobial Agents. 29(2). 191–196. 13 indexed citations
6.
Garrison, Mark W.. (2005). Pharmacodynamic assessment of the activity of high-dose (750 mg) levofloxacin, ciprofloxacin, and gatifloxacin against clinical strains of Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease. 54(1). 51–56. 7 indexed citations
7.
Garrison, Mark W.. (2003). Comparative antimicrobial activity of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. Journal of Antimicrobial Chemotherapy. 52(3). 503–506. 14 indexed citations
8.
9.
Carroll, Karen C., et al.. (1998). Comparison of various in vitro susceptibility methods for testing Stenotrophomonas maltophilia. Diagnostic Microbiology and Infectious Disease. 32(3). 229–235. 31 indexed citations
10.
Garrison, Mark W., et al.. (1998). Levofloxacin: a therapeutic review. Clinical Therapeutics. 20(6). 1049–1070. 84 indexed citations
11.
Garrison, Mark W., et al.. (1997). Influence of pH on the antimicrobial activity of clarithromycin and 14-hydroxyclarithromycin against Haemophilus influenzae using an in vitro pharmacodynamic model. Diagnostic Microbiology and Infectious Disease. 27(4). 139–145. 8 indexed citations
12.
Garrison, Mark W., et al.. (1997). Agranulocytosis Induced by Vancomycin or Ticarcillin/Clavulanate. Annals of Pharmacotherapy. 31(11). 1321–1324. 8 indexed citations
13.
Lewis, James S., et al.. (1997). Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clinical Therapeutics. 19(2). 187–214. 38 indexed citations
14.
Vance‐Bryan, Kyle, T. A. Larson, Mark W. Garrison, et al.. (1992). An in Vitro Pharmacodynamic Model to Simulate Antibiotic Behavior of Acute Otitis Media with Effusion. Pharmaceutical Research. 9(7). 920–924. 8 indexed citations
15.
Garrison, Mark W., et al.. (1991). Therapeutic Advances in the Prevention of Hepatitis B: Yeast-Derived Recombinant Hepatitis B Vaccines. DICP. 25(6). 617–627. 8 indexed citations
16.
Garrison, Mark W., Darwin E. Zaske, & John C. Rotschafer. (1990). Aminoglycosides: Another Perspective. DICP. 24(3). 267–272. 18 indexed citations
17.
Garrison, Mark W., et al.. (1989). Current immunization practices. Postgraduate Medicine. 85(2). 199–210. 3 indexed citations
18.
Garrison, Mark W., John C. Rotschafer, & Kent Crossley. (1989). Suboptimal Effect of Daptomycin in the Treatment of Bacteremias. Southern Medical Journal. 82(11). 1414–1415. 20 indexed citations
19.
Rodvold, Keith A., Randy D. Pryka, Mark W. Garrison, & John C. Rotschafer. (1989). Evaluation of a Two-Compartment Bayesian Forecasting Program for Predicting Vancomycin Concentrations. Therapeutic Drug Monitoring. 11(3). 269–275. 39 indexed citations
20.
Garrison, Mark W. & John C. Rotschafer. (1989). Clinical Assessment of a Published Model to Predict Aminoglycoside-Induced Nephrotoxicity. Therapeutic Drug Monitoring. 11(2). 171–175. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael A. Pfaller Breakdown of academic impact, for papers by P. G. Pitsakis Breakdown of academic impact, for papers by Meridith E. Erwin Breakdown of academic impact, for papers by Helen T. Fernandez Breakdown of academic impact, for papers by Kevin W. Ward Breakdown of academic impact, for papers by Gerald A. Denys Breakdown of academic impact, for papers by C Watanakunakorn Breakdown of academic impact, for papers by A. Evans Breakdown of academic impact, for papers by A Buré Breakdown of academic impact, for papers by Carmen Betriú
Rankless by CCL
2026